Astrovirus Coat Proteins Regulating Complement Cascade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-complement therapies are either too broad in their action, toxic, or not viable due to safety concerns, lacking effective and safe options for treating complement-mediated tissue damage and autoimmune diseases.
Innovation Solution
The use of astrovirus coat proteins or derivatives, either purified or recombinantly produced, to regulate the complement cascade by inhibiting specific pathways, such as the classical or alternative complement pathways, thereby reducing tissue damage and complement-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If cobra venom factor (CVF) is used to deplete complement C3, then complement-mediated tissue damage is reduced, but uncontrolled complement activation occurs leading to prolonged decomplementation and vulnerability to infection
Solution Approach 1:
The invention segments the complement regulation function by using distinct astrovirus coat protein derivatives that can selectively inhibit specific complement pathways (classical or alternative) rather than causing global complement depletion. This allows targeted protection against complement-mediated damage while preserving necessary complement functions for host defense.
Solution Approach 2:
The invention changes the parameter of complement regulation from complete depletion (CVF) to controlled inhibition through astrovirus coat protein derivatives. These derivatives modulate complement activity at specific points in the cascade, altering the degree and specificity of complement suppression to achieve therapeutic effect without causing prolonged decomplementation.
2Object-affected harmful factors
If broad-spectrum anti-complement therapies are used, then complement-mediated damage is reduced, but toxicity and safety concerns increase
Solution Approach 1:
The invention applies local quality by designing astrovirus coat protein derivatives with specific binding affinities for particular complement components or pathways. This allows the therapy to act locally on specific complement pathways responsible for tissue damage while leaving other complement functions intact, thereby reducing systemic toxicity.
Solution Approach 2:
The astrovirus coat protein derivatives serve as intermediary molecules that mediate between the therapeutic goal of complement inhibition and the need for safety. These proteins bind to specific complement components (such as C3 or C5) to prevent their activation or function, providing controlled inhibition without the uncontrolled activation and toxicity associated with CVF.
3Object-affected harmful factors
If current anti-complement therapies are used, then some complement activity is inhibited, but the therapies act too broadly or are not viable due to toxicity
Solution Approach 1:
The invention segments complement pathway inhibition into distinct therapeutic agents targeting specific pathways. Different astrovirus coat protein derivatives can be selected or designed to inhibit either the classical pathway or the alternative pathway, providing adaptable, targeted therapy based on the specific disease mechanism without requiring broad-spectrum suppression.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The astrovirus coat proteins demonstrate efficacy comparable to cobra venom factor in inhibiting complement-mediated lysis, offering a safer and more targeted approach to treating complement-related diseases, including autoimmune and inflammatory conditions.
Implementation Method 1
binding to complement factor C1q
Implementation Method 2
inhibiting complement-mediated lysis
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides a method for modulating the complement cascade by depleting the plasma of the functional activity of complement proteins and thereby reducing or eliminating complement-mediated cell lysis. The invention provides a method for the therapeutic use of coat proteins and derivatives thereof from the Astroviradae family of viruses in the treatment of complement-mediated cell lysis and peptide mediators of inflammation. The invention provides a method for the therapeutic use of coat proteins and derivatives thereof from the Astroviradae family of viruses in the treatment of complement- mediated diseases. Methods are described herein where complement cascade, triggered by either the classical or alternative complement pathways, is prevented from effecting cell lysis and inflammation due to inhibition or depletion of one or more complement components in the serum following administration of astrovirus coat proteins or derivatives.